Understanding Intentional and Unintentional Non-Adherence: A Behavioral Framework for Healthcare Professionals
Medication non-adherence in chronic disease is shaped by many factors and goes far beyond simply forgetting to take a dose.1 It includes both intentional decisions to deviate from treatment and unintentional lapses, which often stem from the same underlying beliefs about medicines.1,2 These patterns can fluctuate over time, with behaviors like drug holidays or white‑coat adherence highlighting why clinicians need to recognize the full spectrum early to identify patients at risk.
What is intentional versus unintentional non-adherence?
Medication adherence is broadly defined as ‘the degree to which a patient follows healthcare provider advice regarding the timing, dosage, and frequency of medication use’. 1 When patients fall short of this, the reasons matter — and understanding them begins with a fundamental distinction in the literature between two types of non-adherence.
Intentional non-adherence is an active, deliberate decision on the part of the patient to deviate from their prescribed regimen.1 This can take many forms, including adjusting doses based on perceived improvement or worsening of symptoms, skipping or adjusting doses to make medication last longer, or stopping treatment altogether without consulting a healthcare provider.1 It may also reflect a rational weighing of perceived risks and benefits of treatment against side effects.3 Contributing factors include patients underestimating the consequences of their condition, concerns about medication side effects, poor patient-physician communication, and personal or religious beliefs about treatment.1
Unintentional non-adherence, by contrast, occurs when patients ‘fail to follow their prescribed treatment despite a willingness to do so’. 1 It is a passive process, driven by forgetfulness, carelessness, or circumstances outside the patient’s control.2,3 In a survey of over 24,000 adults with chronic disease who self-identified as persistent to the prescription medication, 62% reported forgetting to take their medication, 37% had run out of medication, and 23% reported being careless at times — making unintentional non-adherence strikingly common even among patients who consider themselves adherent.2
Intentional and Unintentional Non-Adherence are not as distinct as they may first appear. In practice, patients often exhibit both types of non-adherent behavior simultaneously, further blurring the boundary between them.2
Research shows that unintentional behaviors are predicted by the same underlying medication beliefs — perceived need, concerns about medication, beliefs about treatment efficacy and affordability — that also drive intentional non-adherence 2 This suggests that unintentional non-adherence may function as an early warning sign of future intentional non-adherence, making it a clinically meaningful behavior to identify and address proactively.2
For healthcare professionals, understanding that neither type is truly random or isolated — is the foundation of any meaningful clinical response to poor adherence. Non-adherence is a multifaceted issue influenced by patient, medication, healthcare system, socioeconomic, and geographical factors, and no single explanation or intervention will fit all patients.1
What is a “Drug Holiday” and how is it classified?
A “drug holiday” refers to a period during which a patient temporarily stops taking their medication, either intentionally or as part of a broader pattern of inconsistent adherence. Within the wider spectrum of medication-taking behavior, drug holidays represent a specific and recognisable pattern that sits between consistent adherence and complete discontinuation.3
Based on electronic monitoring data, researchers have identified six distinct day-to-day patterns of medication-taking behavior. Drug holidays feature in two of these: some patients take drug holidays three to four times per year, while others take them monthly or more frequently, often accompanied by additional missed doses in between. This places drug holidays firmly within the category of execution-related non-adherence — describing not whether a patient has stopped therapy altogether, but how consistently they follow their dosing regimen over time.3
For healthcare professionals, it is important to recognize that drug holidays are not simply an occasional lapse. Patients who take frequent drug holidays may be exhibiting the same underlying medication beliefs — such as low perceived need or concerns about side effects — that predict more entrenched intentional non-adherence down the line.2
What does “Adherence Fatigue” mean in long-term therapies?
Medication adherence fatigue, sometimes called pill fatigue, refers to the gradual erosion of medication-taking behavior that occurs over time in patients managing long-term conditions.4-7 It is well established that adherence rates drop rapidly within the first year of treatment for many chronic conditions,1 and that beyond the early period, there appears to be a progressive decline in adherence to prescribed medications over time.3
This decline is not random. Patients who initially persist with therapy may begin to exhibit unintentional non-adherence — forgetting doses, running out of medication, or becoming careless — and these behaviors are predicted by weakening medication beliefs, including lower perceived need and growing concerns about treatment.2 Crucially, these lapses may themselves reinforce disengagement: unintentional non-adherence mediates the relationship between medication beliefs and subsequent intentional non-adherence, suggesting a progressive pathway toward eventual discontinuation.2
Contributing factors include complex regimens, side effect burden, and the asymptomatic nature of many chronic conditions, which reduce the sense of urgency over time.1
Adherence fatigue therefore reflects a cumulative process in which the psychological, practical, and physiological demands of long-term therapy gradually outpace a patient’s motivation and capacity to maintain consistent treatment behavior.
What is “White Coat Adherence” and how common is it?
White coat adherence describes the tendency of patients to improve their medication-taking behavior shortly before and after an appointment with a healthcare provider. It represents a recognized pattern within execution-related non-adherence, whereby patients who are otherwise inconsistent briefly align their behavior with expectations around clinical contact.3,8
It has been observed in several chronic conditions, including cardiovascular disease, asthma, diabetes, epilepsy and glaucoma.3,8 In glaucoma, this short burst of “good behavior” can make intraocular pressure look comfortably controlled in clinic, even if it is not well controlled the rest of the time. In a study of primary open‑angle glaucoma, mean adherence rose from 85.5% to 88.5% in the three days before a visit and then fell from 87.0% to 84.9% afterwards. Among patients who demonstrated a white coat effect, adherence changed by ±13.4% before and after the visit, large enough to be of clinical significance.8
White coat adherence is thought to stem from a mix of practical and psychological factors. As a clinic visit gets closer, the upcoming appointment can act as a simple reminder to take medications more regularly. The prospect of seeing a healthcare provider in person can also play a role, since some people may try to be more consistent with their treatment to avoid disappointing or being judged by their clinician.8
What you can do: Practical steps for healthcare professionals
Healthcare professionals can implement several evidence-based strategies to address different non-adherence patterns in clinical practice:
- Strengthen communication and shared decision-making: Involve patients in treatment choices, provide clear information about side effects and their likely duration, and ensure consistent follow-up — particularly for vulnerable groups like adolescents and the elderly.1
- Simplify treatment regimens where possible. Advocate for once-daily formulations, single-tablet combinations, or alternative routes of administration to reduce pill burden and make adherence more manageable for patients with complex medication needs.1
- Focus on the first six months, when non‑persistence is most likely; use adherence screeners to spot early doubts or misconceptions that can lead to forgetfulness, carelessness and eventually stopping treatment altogether.2
- Ask routinely about “small slips” like forgetting doses or running out of medication, since these unintentional lapses are common and often signal early beliefs that can later lead to intentional non‑adherence.2
- Screen for non-adherence at every visit: Incorporate a simple medication adherence question into routine appointments — similar to recording vital signs — since patient self-report, though imperfect, is specific and predicts future adverse outcomes.3
- Use multimodal interventions for high-risk patients: Single strategies have limited impact; combining approaches such as dose simplification, pill organizers, patient education, and telephone follow-up, produces the most meaningful improvements in adherence.3
- Be alert to white coat adherence as a source of clinical bias: Patients tend to improve their medication-taking in the days immediately surrounding an appointment, which means that clinical measurements taken during a visit, may overestimate how well a patient is managing their treatment day-to-day. Enquire about typical day-to-day adherence behavior rather than recent behavior alone.8
- Proactive conversations with newly diagnosed patients: The white coat effect is more marked early in treatment, when patients are still establishing habits. Exploring patients’ beliefs about personal control over their condition and confidence in their treatment, can help identify those at risk of poor adherence.8
Conclusion
Non-adherence is rarely straightforward. Whether driven by deliberate choice, forgetfulness, fatigue, or the temporary boost of a clinic visit, each pattern reflects distinct underlying beliefs and behaviors. Recognizing these nuances allows healthcare professionals to move beyond assumption and respond with targeted, timely interventions that support patients throughout the full course of treatment.
This article was written with the assistance of generative AI technology and reviewed for accuracy.
FAQ
The quality of communication between a physician and their patient has a direct and measurable impact on adherence. Research across nearly 100 studies found that patients treated by physicians rated with poor communication were significantly more likely to be non-adherent — by almost 20% — compared to those whose physicians communicated well.1 For healthcare professionals, this is a striking finding: the way a clinician communicates may be just as influential on patient outcomes as the treatment they prescribe.
Certain medications contain animal products. Some religions may prohibit the use of bovine or porcine-derived products unless there is no alternative and where religious consensus is not clear, patients could become conflicted. It is important that healthcare professionals are conscious of potential conflicts and that alternatives are offered where available. Examples of medications that include animal derivatives include heparinoids, hormones, and immunoglobins. The shells of many capsule medications may also contain gelatin, and lactose is a common component of tablets. Where available, starch-based capsules could be provided.1
There is no single reliable test, but asking open, non-judgmental questions about a patient’s typical medication-taking routine can help. Patients who report forgetting doses, running out of medication, or being careless are more likely exhibiting unintentional non-adherence,2 while those who describe adjusting or stopping their medication based on how they feel are more likely making deliberate decisions.1 In practice, many patients exhibit both types simultaneously, so it is worth exploring both.2
Yes. Patients who self-identify as adherent still commonly report forgetting doses or being careless, meaning self-perception is not a reliable guide to actual behavior.2 More importantly, unintentional lapses such as occasional skipped doses are predicted by the same underlying medication beliefs that drive intentional non-adherence, suggesting they may be an early warning sign of more significant disengagement down the line.2
Discontinuation is rarely the result of a single factor. It typically reflects a cumulative process in which motivation erodes over time, driven by weakening beliefs about the need for treatment, growing concerns about side effects, the burden of long-term therapy, and the asymptomatic nature of many chronic conditions.1 Understanding which of these factors is most relevant to an individual patient is key to intervening before discontinuation occurs.3
Medication beliefs – particularly patients’ perceived need for treatment and their concerns about it – are among the strongest predictors of both intentional and unintentional non-adherence.2 These beliefs are not fixed. Targeted conversations that explore and gently challenge misconceptions, reinforce the consequences of poor adherence, and build confidence in treatment effectiveness can shift beliefs in a clinically meaningful direction and improve long-term adherence.1 A program for stroke survivors that included a component targeting medication beliefs led to a 10% increase in adherence among participants who completed it compared with those who did not.1
Not necessarily. While some patients may consciously try to improve their behavior ahead of an appointment to avoid clinician disapproval, for others the upcoming visit simply serves as a practical reminder to take their medication more regularly.8 The effect is likely a mixture of both conscious and unconscious motivations, and providers should approach it without assumption or judgment.
No. Research suggests that white coat adherence is more pronounced in patients who are already broadly adherent to their treatment, possibly because they are more engaged with their care overall.8 Patients with poorer baseline adherence may not show the same pre-visit improvement, though they may respond differently after a visit if the appointment reinforces the importance of controlling their condition.8
Adherence should be assessed at every appointment rather than treated as a one-off conversation. Incorporating a simple, non-judgmental adherence question into routine consultations – in the same way that recording vital signs is standard practice – normalises the discussion and makes it easier to identify problems early.3 Given that adherence can fluctuate significantly over time, a single assessment is unlikely to capture the full picture.3
While non-adherence can affect any patient, certain groups warrant closer attention. Newly diagnosed patients are at heightened risk in the early months of treatment, when habits are still forming and the white coat effect may be most pronounced.8 Patients managing complex regimens, those with low health literacy, and those who report low confidence in their ability to control their condition or in the effectiveness of their treatment are also more vulnerable and may benefit from more proactive and frequent follow-up.1,3
